{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:45:26Z","timestamp":1794012326591,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020743","name":"Institute of Energy, Hefei Comprehensive National Science Center","doi-asserted-by":"publisher","award":["GXXT-2022-003, 21KZS202"],"award-info":[{"award-number":["GXXT-2022-003, 21KZS202"]}],"id":[{"id":"10.13039\/100020743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2022e07020038"],"award-info":[{"award-number":["2022e07020038"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13486-5","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:53:17Z","timestamp":1740729197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Min","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"3","key":"13486_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"key":"13486_CR2","doi-asserted-by":"publisher","first-page":"102339","DOI":"10.1016\/j.ctrv.2022.102339","volume":"104","author":"D Trapani","year":"2022","unstructured":"Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G. Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022;104:102339.","journal-title":"Cancer Treat Rev"},{"key":"13486_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Sem Cancer Biol. 2020;60:14\u201327.","journal-title":"Sem Cancer Biol"},{"key":"13486_CR4","unstructured":"Minkyu K, Jisoo P, Mehdi B, Kyumin K, Ajda R, Maya M, Margaret S, Michael JM, Patrick OL, Denise W et al. A protein interaction landscape of breast cancer. Science 2021;374(6563)."},{"key":"13486_CR5","doi-asserted-by":"crossref","unstructured":"Leila D, Sara C, Jamie A, Anna G-N, Craig L, Cecilia W, Karen AP, Michael TP, Cristina F, Qin W et al. Breast Cancer Risk Genes - Association Analysis in more than 113,000 women. N Engl J Med 2021;384(5).","DOI":"10.1056\/NEJMoa1913948"},{"issue":"1","key":"13486_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13058-022-01507-1","volume":"24","author":"G Wei","year":"2022","unstructured":"Wei G, Teng M, Rosa M, Wang X. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes. Breast Cancer Res. 2022;24(1):11.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"13486_CR7","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.7150\/thno.52190","volume":"11","author":"Z Shi","year":"2021","unstructured":"Shi Z, To SKY, Zhang S, Deng S, Artemenko M, Zhang M, Tang J, Zeng JZ, Wong AST. Hypoxia-induced Nur77 activates PI3K\/Akt signaling via suppression of Dicer\/let-7i-5p to induce epithelial-to-mesenchymal transition. Theranostics. 2021;11(7):3376\u201391.","journal-title":"Theranostics"},{"key":"13486_CR8","unstructured":"Olga M-S, Nuria C, Tom\u00e1s P, Barbara A, Maria V, Blanca G-F, Esther S, Francesco S, Benedetta C, Fara B-M et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res 2020;22(1)."},{"key":"13486_CR9","doi-asserted-by":"crossref","unstructured":"Dwan-Ying C, Wei-Li M, Yen-Shen L. Role of Alpelisib in the treatment of PIK3CA-Mutated breast Cancer: patient selection and clinical perspectives. Ther Clin Risk Manag 2021;17(0).","DOI":"10.2147\/TCRM.S251668"},{"key":"13486_CR10","doi-asserted-by":"crossref","unstructured":"Jeffrey AE, Liang C, Xiaohong T, Katherine C, Alexander RG, Rabi U, Michel M, Kate M, Samanthi AP, Youngchul S et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14(12).","DOI":"10.1038\/nm.1890"},{"key":"13486_CR11","doi-asserted-by":"crossref","unstructured":"Aldrick R, Myl\u00e8ne S, Rapha\u00ebl S, Marc-Antoine A, Nelly B, Giulia H, Julie V, Jocelyne H, Ren\u00e9 A, Jean-Fran\u00e7ois M et al. Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection. BMC Cancer 2019;19(1).","DOI":"10.1186\/s12885-019-5365-2"},{"key":"13486_CR12","doi-asserted-by":"crossref","unstructured":"David AF, Honyin C, Benjamin DH, Shubha B, Lewis CC. Robert T A: the PI3K pathway in Human Disease. Cell 2017;170(4).","DOI":"10.1016\/j.cell.2017.07.029"},{"key":"13486_CR13","doi-asserted-by":"crossref","unstructured":"Daniela M, Alexandra T, Iulia-Ioana S-S, Silviu Constantin B, Constantin S, Maria G. PI3K\/AKT\/mTOR signaling pathway in breast Cancer: from Molecular Landscape to clinical aspects. Int J Mol Sci 2020;22(1).","DOI":"10.3390\/ijms22010173"},{"key":"13486_CR14","doi-asserted-by":"crossref","unstructured":"Miricescu D, Totan A, Stanescu S, Badoiu II, Stefani SC, Greabu C. M: PI3K\/AKT\/mTOR signaling pathway in breast Cancer: from Molecular Landscape to clinical aspects. Int J Mol Sci 2020;22(1).","DOI":"10.3390\/ijms22010173"},{"key":"13486_CR15","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418).","DOI":"10.1038\/nature11412"},{"issue":"1","key":"13486_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41467-023-35789-6","volume":"14","author":"ML Jenkins","year":"2023","unstructured":"Jenkins ML, Ranga-Prasad H, Parson MAH, Harris NJ, Rathinaswamy MK, Burke JE. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. Nat Commun. 2023;14(1):181.","journal-title":"Nat Commun"},{"issue":"5","key":"13486_CR17","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1002\/cam4.5314","volume":"12","author":"K Li","year":"2023","unstructured":"Li K, Cao L, Li C, Wu J, Chen B, Zhang G, Li X, Wen L, Jia M, Wei G, et al. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. Cancer Med. 2023;12(5):5195\u2013208.","journal-title":"Cancer Med"},{"issue":"1","key":"13486_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"key":"13486_CR19","doi-asserted-by":"crossref","unstructured":"Expert consensus on the clinical application of PI3K\/AKT\/mTOR inhibitors in the treatment of advanced breast cancer. Cancer innovation. 2022;1(1):25\u201354.","DOI":"10.1002\/cai2.10"},{"issue":"7793","key":"13486_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578(7793):122\u20138.","journal-title":"Nature"},{"issue":"6","key":"13486_CR21","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","volume":"47","author":"N Jiang","year":"2020","unstructured":"Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587\u2013629.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"13486_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andr\u00e9 F, Loibl S, Loi S, Garcia-Murillas I, et al. The Genetic Landscape and Clonal evolution of breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403.","journal-title":"Cancer Discov"},{"issue":"9","key":"13486_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2443","volume":"8","author":"LM Amzel","year":"2008","unstructured":"Amzel LM, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer. 2008;8(9):665\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"7418","key":"13486_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits","year":"2012","unstructured":"Comprehensive molecular portraits. Of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"4","key":"13486_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395\u2013402.","journal-title":"Cancer Cell"},{"issue":"2","key":"13486_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/annonc\/mdp304","volume":"21","author":"Y Kataoka","year":"2010","unstructured":"Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2010;21(2):255\u201362.","journal-title":"Ann Oncol"},{"issue":"5","key":"13486_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","volume":"15","author":"TT Junttila","year":"2009","unstructured":"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429\u201340.","journal-title":"Cancer Cell"},{"issue":"6","key":"13486_CR28","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1002\/jcb.26687","volume":"119","author":"N Sobhani","year":"2018","unstructured":"Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287\u201392.","journal-title":"J Cell Biochem"},{"issue":"6","key":"13486_CR29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1158\/1078-0432.CCR-22-2115","volume":"29","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, et al. Biology and Targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29(6):1056\u201367.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"13486_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al. Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast Cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"13486_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12967-023-04841-w","volume":"22","author":"M Tufail","year":"2024","unstructured":"Tufail M, Hu JJ, Liang J, He CY, Wan WD, Huang YQ, Jiang CH, Wu H, Li N. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway. J Translational Med. 2024;22(1):15.","journal-title":"J Translational Med"},{"issue":"4","key":"13486_CR32","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne IM, Andr\u00e9 F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25(4):e139\u201351.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13486-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13486-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:53:23Z","timestamp":1740729203000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13486-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13486"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13486-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed the ethical guidelines of the Declaration of Helsinki in 1964 and its subsequent amendments. The study received approval from the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (No. YX2023-206). This study declared that informed consent has been obtained from all participating patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}